The Non-Compete Chill Has Passed: Bristol-Myers, MedImmune Settle Over I-O Star

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.